MarginsXMarginsX
Home › Markets › Health Care › MAIA

MAIA Biotechnology Inc. (MAIA)

MAIA trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.01
+1.00% on the day
Market cap
$62.4M
Micro cap
Revenue · 2024
$0
Prior year not contiguous
Net income · 2024
-$23.3M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2024-12-31, https://www.sec.gov/Archives/edgar/data/1878313/000095017025043190/0000950170-25-043190-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2024-12-31.

Profile

FieldValue
TickerMAIA on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryNot reported by the screener
IPO year2022
SEC CIK0001878313
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2024

LineValue
Revenue$0
Net income-$23.3M
Operating income-$17.0M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growthNo prior-year revenue to compare
Cash$0
Total assets$10.2M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
0.0 months
$0 cash at September 30, 2026
Share count, 1 year
+66.7%
2025-11-07 to 2026-11-09 · +334.4% over 3 years
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
$996K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"Based on the cost control measures implemented, the Company believes the substantial doubt to continue as a going concern for at least 12 months from the date these financial statements were issued is reasonably alleviated."
10-Q 2026-11-09
Cash and burn$0 cash; operating cash flow -$6.3M a quarter.Report 2026-09-30
Shares outstanding61,750,308 (2026-11-09); 37,032,307 a year earlier; 14,213,511 three years earlier.Cover page 2026-11-09
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-05-14
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorGrant Thornton LLP, Charlotte, North Carolina, United StatesPCAOB Form AP 2026-03-25
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $996K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$7.2M-$6.3M$0No debt tagsNeeds four quarters10-Q 2026-11-09
Q2 2026
2026-06-30
Not filed-$7.9M-$6.8M$0No debt tagsNeeds four quarters10-Q 2026-11-09
Q1 2026
2026-03-31
Not filed-$6.4M-$5.3M$0No debt tagsNeeds four quarters10-Q 2026-11-09
Q4 2025
2025-12-31
Not filed-$3.6M-$7.0M$0No debt tagsNeeds four quarters10-K 2026-03-23
Q3 2025
2025-09-30
Not filed-$8.9M-$3.5M$0No debt tagsNeeds four quarters10-Q 2026-11-09
Q2 2025
2025-06-30
Not filed-$5.3M-$4.1M$0No debt tagsNeeds four quarters10-Q 2026-11-09
Q1 2025
2025-03-31
Not filed-$4.5M-$4.2M$0No debt tagsNeeds four quarters10-Q 2026-11-09
Q4 2024
2024-12-31
Not filed-$3.6M-$3.9M$0No debt tags$010-K 2026-03-23

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-10-07
Latest annual report10-K2026-03-23
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-10-06
Latest proxyDEFA14A2026-05-19

Source: SEC EDGAR submissions feed, 504 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-5.7%
1 month-13.8%
3 months-25.4%
Year to date-34.6%
1 year-1.0%
From 52-week high-66.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ACRVAcrivon Therapeutics Inc.$1.46+0.69%$62.6M
LFVNLifevantage Corporation Common Stock (Delaware)$4.77-4.02%$60.5M
GOSSGossamer Bio Inc.$10.98+0.09%$67.2M
TENXTenax Therapeutics Inc.$1.48-8.64%$67.4M
FBIOFortress Biotech Inc.$1.71-9.04%$57.7M
ZYBTZhengye Biotechnology Holding Limited$1.43-4.67%$67.8M
BOLDBoundless Bio Inc.$2.41-3.60%$56.9M
MNOVMedicinova Inc$1.34-3.94%$68.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier